Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast canc... by Qiang Zhang, Mozhi Wang, Yumeng Li, Hengjun Zhang, Yusong Wang, Xiuyun Chen, Litong Yao, Mingke Cui, Haoran Dong, Xiang Li, Jian Liu, Bo Zhu, Yingying Xu

Get full text